Search for: "Anda Pharmaceuticals, Inc"
Results 61 - 80
of 605
Sort by Relevance
|
Sort by Date
7 Aug 2020, 9:15 am
A copy of the Opinion is attached. [1] Plaintiffs, Bristol-Myers Squibb Company and Pfizer Inc., had originally filed the action against at least twenty-five (25) defendant pharmaceutical companies. [read post]
31 Jul 2020, 9:40 am
For the reasons described below, we affirm.The matters at issue:In 2016, Takeda sued Mylan Pharmaceuticals Inc. forpatent infringement based on Mylan’s recently submittedAbbreviated New Drug Application (“ANDA”) for a genericversion of Takeda’s Colcrys® product, which is a brandedversion of the drug colchicine. [read post]
7 Jul 2020, 6:04 am
A Paragraph IV certification is an ANDA filer’s statement that it intends to market its bioequivalent pharmaceutical product before the expiration of a patent listed as covering that product because the ANDA filer believes such patent is either not infringed or invalid. [read post]
8 Apr 2020, 9:59 pm
Mylan Pharmaceuticals Inc. [read post]
29 Mar 2020, 9:55 pm
Hospira, Inc. [read post]
14 Jan 2020, 9:10 pm
The issue arose in ANDA litigation, where the District Court found claim 6 of U.S. [read post]
8 Jan 2020, 8:57 pm
The case arose in ANDA... [read post]
8 Jan 2020, 11:16 am
” Intervet Inc. v. [read post]
14 Oct 2019, 2:15 pm
Actavis Laboratories UT, Inc. affirming the U.S. [read post]
30 Aug 2019, 4:15 am
’s (“Actavis’s”) generic Abbreviated New Drug Application (“ANDA”) product infringed claims of patents owned by Nalpropion Pharmaceuticals (“Nalpropion”) and that the asserted claims were not invalid. [read post]
30 Aug 2019, 4:15 am
’s (“Actavis’s”) generic Abbreviated New Drug Application (“ANDA”) product infringed claims of patents owned by Nalpropion Pharmaceuticals (“Nalpropion”) and that the asserted claims were not invalid. [read post]
27 Aug 2019, 2:03 am
In contrast to its decision in Nuvo Pharmaceuticals, Inc. v. [read post]
20 Aug 2019, 9:59 pm
Noonan -- Last week, the Federal Circuit reversed findings of non-obviousness and affirmed (over Chief Judge Prost's dissent) a finding that claims asserted in ANDA litigation were not invalid for failure to satisfy the written description requirement in Nalproprion Pharmaceuticals, Inc. v. [read post]
15 Aug 2019, 11:16 am
by Dennis Crouch Nalpropion Pharmaceuticals, Inc. v. [read post]
8 May 2019, 7:14 am
Genus Lifesciences Inc. v. [read post]
6 May 2019, 9:58 pm
Noonan -- Last Friday, the Federal Circuit affirmed a decision by the District Court that Defendants Actavis LLC and Teva Pharmaceuticals did not show by clear and convincing evidence that the claims asserted by Endo Pharmaceuticals Inc. and Mallinckrodt LLC were obvious, in Endo Pharmaceuticals Inc. v. [read post]
Medical Treatment Patent Claims Held Patentable Subject Matter Under the Alice/Mayo Section 101 Test
30 Apr 2019, 7:10 pm
In Vanda Pharmaceuticals Inc. v. [read post]
9 Apr 2019, 8:03 pm
Teva Pharmaceuticals USA, Inc., 395 F.3d 1364 (Fed. [read post]
4 Apr 2019, 6:15 am
(Alembic) and Breckenridge Pharmaceuticals, Inc. [read post]
4 Apr 2019, 6:15 am
(Alembic) and Breckenridge Pharmaceuticals, Inc. [read post]
